Manipal Health Enterprises Limited has confirmed the appointment of KFin Technologies Limited as its Registrar and Share Transfer Agent (R&SA). The appointment, effective from February 13, 2025, ensures compliance with Regulation 7(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This structural update standardizes share transfer processes for investors.

The company disclosed this appointment in a filing dated August 5, 2026, submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). The disclosure was made under Regulation 7(1) of the SEBI LODR Regulations, 2015, which mandates timely intimation of changes in R&SA appointments to ensure transparency and operational continuity for shareholders.

KFin Technologies Limited, headquartered at 301, The Centrium, 3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada, Kurla (West), Mumbai, Maharashtra, India, 400 070, continues to act in this capacity. The firm handles critical investor services including share transfers, transmission of shares, and maintenance of the register of members.

The filing was signed by Sathish K R, Company Secretary and Compliance Officer of Manipal Health Enterprises Limited, bearing Membership No. A15203. The digital signature timestamp indicates the submission occurred on August 5, 2026, at 11:31:54 IST.

Key Details

This appointment aligns with standard corporate governance practices for listed entities in India, ensuring that shareholder records are maintained by a specialized agency approved by regulatory standards.

Manipal Health Enterprises Limited has confirmed that Sathish K R continues to serve as its Compliance Officer, a position he has held since November 25, 2025. The disclosure, filed with the Bombay Stock Exchange and National Stock Exchange on August 5, 2026, ensures transparency regarding the company’s adherence to regulatory governance standards. This continuity in the compliance function supports the company’s ongoing commitment to maintaining robust corporate governance frameworks as mandated by market regulators.

The intimation was submitted under Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the filing incorporates details required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026, dated January 30, 2026. These regulatory references underscore the structured approach the company takes toward statutory disclosures and compliance officer appointments.

Sathish K R, who holds ICSI Membership No. A15203, serves concurrently as the Company Secretary and General Counsel of Manipal Health Enterprises Limited. He has been associated with the company since August 14, 2019, overseeing regulatory strategy, legal compliance, and corporate governance functions. His dual role ensures integrated oversight of legal and compliance matters within the organization.

With over 25 years of experience in legal, company secretarial, and compliance domains, Sathish K R brings extensive industry knowledge to his role. He holds a bachelor’s degree in law from Bengaluru University and a master’s degree in law with distinction in commercial and corporate law from Queen Mary and Westfield College, University of London. Prior to joining Manipal Health Enterprises Limited, he worked with prominent organizations including Bosch Limited, GE Bayer Silicones (India) Private Limited, Essilor Manufacturing India Private Limited, and Siemens VDO Automotive Limited.

Governance Continuity

The retention of Sathish K R as Compliance Officer reflects stability in the company’s governance structure. His long-standing association with the firm since 2019 provides institutional memory and consistent interpretation of evolving regulatory requirements. For investors, this continuity signals a mature compliance infrastructure capable of navigating complex regulatory landscapes without disruption. The explicit mention of his qualifications and prior experience in the filing further reinforces the credibility of the company’s internal controls.